Bioanalytics – Biomolecular
Biopharmaceuticals products are nowadays a fast-growing class of therapeutics that represent a critical step forward in the treatment of many severe auto-immune diseases. Nevertheless, for some patients these biotherapeutics induce an activation of the immune system, leading to the formation of antibodies against the drug (ADAs).
Many factors (patient-, disease- or product-related) may influence the potential risk of biotherapy immunogenicity but the relative contributions of these factors to the development of inhibitors is currently not fully understood and still remain to be deciphered.
In this context, the IMI-funded ABIRISK consortium has been created in order to provide an integrated approach to study biotherapy immunization, bringing together a large network of researchers from basic to clinical immunology.
One of the aims of the ABIRISK consortium was to generate tools to predict how individual patients
are likely to respond to biotherapies. For this objective, the consortium setted up a real-world observational multicohort of patients suffering from four different auto-immune diseases (multiple sclerosis, rheumatoid arthritis, Crohn’s disease and ulcerative colitis), naive for the studied biotherapies. Patient were monitored during twelve months. ADA concentrations were first measured at baseline and at defined timepoints. Bio-clinical and genetic data were collected.
In order to identify common immunogenetic pathways, we have considered a cross-diseases strategy for the association and prediction analyses of the first ADA occurrence. The results of these analyses will be presented and discussed.